<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04753996</url>
  </required_header>
  <id_info>
    <org_study_id>20-012867</org_study_id>
    <nct_id>NCT04753996</nct_id>
  </id_info>
  <brief_title>Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients</brief_title>
  <official_title>Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to create a collection of bile, bile duct brushings and&#xD;
      medical information from people with Primary Sclerosing Cholangitis (PSC) and controls to&#xD;
      learn more about changes that occur in the liver.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will ask participants to provide bile and/or bile duct cytology brushings at time&#xD;
      of endoscopic retrograde cholangiopancreatography (ERCP) or cholecystectomy (gallbladder&#xD;
      removal). The bile and brushings will be used to generate and perpetuate bile-derived&#xD;
      organoids using an established matrigel-based protocol. These organoids will then be used in&#xD;
      downstream experiments to better understand disease-specific alterations to biological&#xD;
      pathways informative of disease pathogenesis&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants in study.</measure>
    <time_frame>20 years</time_frame>
    <description>Number of participants in study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of samples (per type)</measure>
    <time_frame>20 years</time_frame>
    <description>Number of samples collected (bile liquid, biliary cells)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinical phenotypes and/or observations.</measure>
    <time_frame>20 years</time_frame>
    <description>Number of clinical phenotypes and/or endpoints observed (i.e. disease progression, liver ca development, organoids.)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Primary Sclerosing Cholangitis</condition>
  <condition>PSC</condition>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Primary Sclerosing Cholangitis (PSC)</arm_group_label>
    <description>Subjects diagnosed with Primary Sclerosing Cholangitis (PSC) will be asked to provide bile and/or brush cytology at time of endoscopic retrograde cholangiopancreatography (ERCP) or cholecystectomy (gallbladder removal).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (non-PSC)</arm_group_label>
    <description>Subjects without a diagnosis of Primary Sclerosing Cholangitis (PSC) will be asked to provide bile and/or brush cytology at time of endoscopic retrograde cholangiopancreatography (ERCP) or cholecystectomy (gallbladder removal).</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Collection of bile and biliary brushings collected at time of endoscopic retrograde&#xD;
      cholangiopancreatography (ERCP) or cholecystectomy (gallbladder removal).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with Primary Sclerosing Cholangitis (PSC) and controls without PSC will be able to&#xD;
        participate in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        PSC&#xD;
&#xD;
          -  Patients diagnosed with PSC between the age of 18 and 85.&#xD;
&#xD;
          -  The diagnosis of PSC will be based on standard PSC criteria including clinical and&#xD;
             biochemical evidence of chronic cholestasis of at least six months duration, positive&#xD;
             cholangiographic findings and compatible liver biopsies if available.&#xD;
&#xD;
          -  Women with PSC of childbearing potential and pregnant women will be offered enrollment&#xD;
             because there is no risk to an unborn child in this investigation. Patients with PSC&#xD;
             and Cholangiocarcinoma will be included.&#xD;
&#xD;
        Controls&#xD;
&#xD;
        â€¢ Controls without history of PSC or evidence of other chronic liver disease of either&#xD;
        gender that will participate in this study should be between the ages of 18-85.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unable to provide inform consent.&#xD;
&#xD;
          -  Prisoners and institutionalized individuals.&#xD;
&#xD;
          -  PSC with orthotopic liver transplantation&#xD;
&#xD;
          -  History of Roux En Y procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konstantinos Lazaridis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erik Schlicht, CCRP</last_name>
    <phone>(507) 284-4212</phone>
    <email>schlicht.erik@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jackie Bianchi</last_name>
    <phone>(507) 266-0346</phone>
    <email>bianchi.jackie@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik M Schlicht, B.A.,CCRP</last_name>
      <phone>507-284-4312</phone>
      <email>schlicht.erik@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jackie Bianchi</last_name>
      <phone>507-266-0346</phone>
      <email>bianchi.jackie@mayo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Konstantinos N. Lazaridis, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

